Skip to main navigation menu Skip to main content Skip to site footer

Review article: Biomedical intelligence

Vol. 145 No. 1112 (2015)

Only conflicts of interest?

  • Reto Obrist
Cite this as:
Swiss Med Wkly. 2015;145:w14120


The current situation of the biomedical sciences is critically discussed. It can be summarized as follows: 1. We have to acknowledge the presence of a serious credibility problem, which might undermine the foundations of medical science. ("Sliding on a slippery slope") 2. Multiple forces going beyond simple conflicts of interest push medical science further down the slippery slope. ("Who is pushing?") 3. The public awareness of something seriously wrong with medical science is mounting on all levels of our multimedia society. ("Looking into the media mirror") 4. Technical corrective measures may be easily implemented, however, to change an expanding and "successful" science culture actually destroying it's own foundations will need a sustained effort by the medical and scientific community on all levels. ("Look away - or act?")


  1. Ioannidis JPA; Why most published research findings are false. PloS Med 2005;2(8):e124 DOI:10.1371/journal.pmed.0020124
  2. Arrowsmith J. Phase II failures: 2008–2010. Nat Rev Drug Discov. 2011;10(5):328–9.
  3. Prinz F, Schlange T, Asadullah K. Believe it or not: how much can we rely on published data on potential drug targets? Nat Rev Drug Discov. 2011;10(9):712–3.
  4. Obrist R, Biollaz J. Klinische Forschung zwischen Industrie und Ärzteschaft. Schweiz Ärzteztg. 2009;90(41):1569–71. German.
  5. Ebrahim S, Sohani ZN, Montoya L, Agarwal A, Thorlund K, Mills EJ, et al. Reanalyses of Randomized Clinical Trial Data. JAMA. 2014;312(10):1024–32. doi:10.1001/jama.2014.9646.
  6. Lundberg GD. II. Perspective from the Editor of JAMA, The Journal of the American Medical Association. Bull Med Libr Assoc. 1992;80(2):110–4.
  7. Garfield E. In truth, the “flood” of scientific literature is only a myth. Scientist. 1991;Sept. 2:11–25; cited by Lundberg GD [6].
  8. MacLeod MR, Michie S, Roberts I, Dimagl U, Chalmers I, Ionnidis JPA, et al. Biomedical Research: Increasing value, reducing waste [Comment]. Lancet. 2014;383:101–4.
  9. Chalmers I, Glasziou P. Avoidable waste in the production and reporting of research evidence [Viewpoint]. Lancet. 2009;374:86–9.
  10. ICH GxP: International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH): ICH HARMONISED TRIPARTITE GUIDELINE FOR GOOD CLINICAL PRACTICE E6(R1) (1996)
  11. Loder E, Godlee F, Barbour V, Winker M, PLOS Medicine editors. Restoring the integrity of the clinical trial evidence base. Calling researchers and editors to help restore invisible and abandoned trials [editorial]. BMJ. 2013; (epub 2013June13) 346:f3601 DOI: 10.1136/bmj.f3601
  13. Conflict of Interest in Medical Research, Education, and Practice; Bernard Lo and Marilyn J. Field, Editors; Committee on Conflict of Interest in Medical Research, Education, and Practice; Institute of Medicine of the National Academies (2009)
  14. WMA Declaration of Helsinki Ethical Principles for Medical Research involving Human Subjects. Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and last amended 2013.
  15. Stamatakis E, Weiler R, Ioannidis JPA. Undue industry influences that distort healthcare research, strategy, expenditure and practice: a review. Eur J Clin Invest. 2013;43(5):469–75.
  16. Fanelli D. How many scientists fabricate and falsify research? A systematic review and meta-analysis of survey data. PloS ONE. 2009;4(5):e5738; DOI: 10.1371/journal.pone 0005738
  17. Fang FC, Steen RG, Casadevall A. Misconduct accounts for the majority of retracted scientific publications. PNAS early edition 2012;
  18. Song F, Parekh S, Hooper L, Loke YK, Ryder J, Sutton AJ, et al. Dissemination and publication of research findings: updated review of related biases. Health Technol Assess. 2010;14(8):ii, ix-x. DOI: 19.2210/hta14080
  19. Riveros C, Dechartres A, Perrodeau E, Haneef R, Boutron I, Ravaud P. Timing and Completeness of Trial Results Posted at and Published in Journals. PLoS Medicine. 2013;10(12):e1001566. DOI:10.1371/journal.pmed.1001566
  20. Choudry NK, Stelfox HT, Detsky AS. Relationships between authors of clinical practice guidelines and the pharmaceutical industry. JAMA. 2002;287:612–7.
  21. Niederer A. Übertreibungen in universitären Pressemitteilungen. NZZ 18.12.2014, basierend auf Sumner P, Vivian-Griffiths S, Boivin J, et al. The association between exaggeration in health related science news and academic press releases: retrospective observational study. BMJ. 2014;349:g7015 DOI: 10.136/bmj.g7015
  22. Nassim Nicholas Taleb, Susanne Held. Antifragilität: Anleitung für eine Welt, die wir nicht verstehen. (2013) Albrecht Knaus Verlag, pg 541. German.
  23. Palazzo G, Krings F, Hoffrage U. Ethical Blindness. J Bus Ethics. 2012;109(3):323–38.
  24. Hoffmann, Christoph. Die Arbeit der Wissenschaften. (2013) Zürich-Berlin: diaphanes. German.
  25. Palazzo G, Hoffrage U. Unethical decision making in organizations. (2014 MOOC course)
  26. Verhaltenskodex der pharmazeutischen Industrie in der Schweiz über die Zusammenarbeit mit Fachkreisen und Patientenorganisationen (Pharma-Kooperations-Kodex); ScienceIndustries, Interpharma, VIPS (2013).–d.pdf. German.
  27. Lotter W. Deal? Brand eins, Thema «Vertrauen», 2014;(10)36–44. German.
  30. Frevert U. Vertrauensfragen: Eine Obsession der Moderne. Munich: C. H. Beck; 2013. German.
  31. Ragnar E. Löfstedt. Risk Management in a Post-Trust Society. Basingstoke: Palgrave MacMillan; 2005.
  32. Lehrer J. The Truth Wears Off. Is there something wrong with the scientific method? The New Yorker 2010; Dec. 13.
  33. Freedman DH. Lies, Damned Lies, and Medical Science. The Atlantic 2010;(11)
  34. Angell M. The truth about the Drug Companies, How they deceive us and what to do about it. New York: Random House; 2004.
  35. Angell M. Drug Companies & Doctors: A Story of Corruption. The New York Review of Books; 2009, January 15
  36. Weiss B. Dr. Schwindel und Prof. Schmu. Brand eins Thema «Vertrauen». 2014;10:118–25. German.
  37. Ben Goldacre; Bad Pharma. (2012)London: Fourth Estate; 2012.
  38. Gøtsche PC. Deadly medicines and organized crime. London, Mew York: Radcliffe Publishing; 2013.
  39. Spielmans GI, Parry PI. From Evidence-based Medicine to Marketing-based Medicine: Evidence from Internal Industry Documents. J Bioeth Inq. 2010;7(1):13–29.
  40. Deyo RA, Patrick DL. Hope or Hype. The obsession with medical advances and the high cost of false promises. New York: AMACOM; 2005.
  41. DW: Top Stories World.. High doses of medical corruption worldwide. Health. 6 Jan. 2013.
  42. Exhibit Stauffacher book shop: on a single visit on 30. June 2014 in a major book shop in Bern I found a prominent exhibit of 5 critical books about doctors/dentists; Werner Bartens: Das sieht aber gar nicht gut aus; Gunter Frank: Gebrauchsanweisung für Ihren Arzt; Michael Imhof: Eidesbruch; Peter Volmer: Darfs noch eine Hüfte sein? Tanja Wold: Murks im Mund;
  43. Ankier SI. Dishonesty, Misconduct and Fraud in Clinical Research: an International Problem. J Int Med Res. 2002;30:357–65.
  44. URLs: or
  45. Geyman J. The Corrosion of Medicine, Can the profession reclaim its moral legacy? Monroe ME; Common Courage Press: 2008.
  46. Malka S, Gregori M. Vernebelung, Wie die Tabakindustrie die Wissenschaft kauft. Zürich: Orell Füssli Verlag AG: 2005. German.
  47. Office of Research Integrity (ORI) of the Department of Health and Human Services;
  48. Raeburn P; Retraction Watch awarded a two-year, $400,000 grant from the MacArthur Foundation. Knight Science Journalism at MIT; KSJ Tracker December 15, 2014;–grant-from-the-macarthur-foundation/
  49. Swiss road map for research infrastructures. State Secretariat for Education, Research and Innovation (SERI);
  50. Steinbrook R. Online disclosure of physician – industry relationship [Perspective]. N Engl J Med. 2009;360(4):325–7.
  51. Agrawal S, Brennan N, Budetti P. The Sunshine Act — Effects on Physicians [Perspective]. N Engl J Med. 2013;368:2054–7. DOI: 10.1056/NEJMp1303523.
  52. Verhaltenskodex der pharmazeutischen Industrie in der Schweiz über die Zusammenarbeit mit Fachkreisen und Patientenorganisationen (Pharma-Kooperations-Kodex) vom 6. September 2013 (Stand: 1. Mai 2014) ScienceIndustries, Interpharma, Vips. German.
  53. USA:
  54. WHO:
  55. Switzerland:
  56. Scientific Integrity (2008); Collaboration between the medical profession and industry (2013);
  57. Ioannidis JPA. How to make more published research true. PloS Med. 2014;11(10):1–6; e1001747. DOI: 10.1371/journal.pmed. 1001747.
  58. Olson S, Downey AS (rapporteurs); Sharing clinical research Data. Workshop summary. IOM,
  59. Johnson VE. Revised standards for statistical evidence. PNAS. 2013;110:19313–7.
  60. Richard H. Thaler, Cass R. Sunstein. Nudge: Improving decisions about health, wealth and happiness. London; Penguin: 2009.
  61. ICMJE. Recommendations for the conduct, reporting, editing, and publication of scholarly work in medical journals. 2013.
  62. Nature Announcement: Reducing our irreproducibility. Nature. 2013;496:398.
  63. Bastian H. A stronger post-publication culture is needed for better science. PLOS Med. 2014;11:e1001772.
  64. Silvermann E. Should research fraud be a crime? A reader poll. The Wall Street Journal Pharmalot blog, 2014, July 16.
  65., Is it time for a retraction penalty? 31 comments!
  66. Kullmann B in the Wall Street Journal blog thread “Scientists’ Elusive Goal: Reproducing Study Results.”